FDA approves a second Alzheimer’s drug that can modestly slow disease
The Food and Drug Administration approved Eli Lilly’s Kisunla on Tuesday, July 2, 2024 for mild or early cases of dementia caused by Alzheimer’s. (Eli Lilly and Company via AP) Approved by the FDA on Tuesday, Eli Lilly’s Kisunla is only the second drug shown to delay cognitive decline in mild or early cases of…